Coherus Oncology (CHRS) Fundamental Analysis: Revenue, Earnings & Valuation

4.39 / 10

Netural

Fundamental score is moderate (4.4/10). Inventory turnover (3.74) and cost‑of‑sales ratio (32.76%) are favorable, while revenue growth (59.81% YoY) and income‑tax ratio (0%) are weak. Interest coverage is solid (34.91). Overall health is average with mixed factor signals.

Analysis Checks(5/10)

Revenue-MV

Value-0.89

Score3/3

Weight50.60%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value59.81

Score0/3

Weight-10.86%

1M Return-2.75%

Inventory turnover ratio

Value3.74

Score2/3

Weight-3.19%

1M Return-0.66%

Accounts receivable turnover ratio

Value0.65

Score1/3

Weight-7.16%

1M Return-1.57%

PB-ROE

Value-0.41

Score1/3

Weight26.83%

1M Return5.22%

Income tax / Total profit (%)

Value0.00

Score0/3

Weight-6.47%

1M Return-1.54%

Fixed assets turnover ratio

Value21.51

Score3/3

Weight3.78%

1M Return0.79%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-3.21%

1M Return-0.73%

Cost of sales ratio (%)

Value32.76

Score3/3

Weight4.00%

1M Return0.79%

Asset-MV

Value-0.55

Score1/3

Weight45.67%

1M Return7.28%

Is CHRS undervalued or overvalued?

CHRS scores 4.39/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, 398.43% net margin, 1.58 P/E ratio, 4.35 P/B ratio, and 472.00% earnings growth, these metrics solidify its Netural investment rating.